ARA-290 is an experimental peptide derived from erythropoietin (EPO) and designed to target tissue-protective pathways without stimulating red blood cell production. It is being studied for nerve pain and inflammation, with evidence still limited to early human trials.
Search “ARA-290” and you’ll find confident claims about dosing and results. The reality is narrower: ARA-290 is an experimental peptide, still in Phase II human trials for nerve pain.
BEST FOR
Adults with small-fiber or diabetic neuropathy pain not resolved by standard treatment
METHOD
Subcutaneous injection, self-administered under provider guidance
FREQUENCY
Provider-set, based on your labs and course length
All information regarding products and services on this site are for educational purposes only. Dynamis Online is not a pharmacy and does not manufacture, distribute, or ship any medications discussed on this site. Our licensed medical professionals work with you to develop a personalized treatment plan that fits your unique health goals. All products and medications are manufactured and distributed by independent, third-party vendor pharmacies and are routinely inspected by both state and federal agencies for safety and efficacy.
Human trials recorded meaningful drops in neuropathic pain, with a sarcoidosis pilot study improving symptom scores by week four and a type 2 diabetes trial improving PainDetect scores.
In the type 2 diabetes trial, ARA-290 was linked to improved HbA1c, cholesterol-to-HDL ratio, and triglycerides, though these were secondary endpoints in a small study.
A Phase 2b trial measured a real increase in corneal nerve fiber density and regenerating nerve fibers after 28 days, a physical marker beyond symptom relief alone.
The sarcoidosis pilot trial also recorded improvement on the SF-36 quality of life scale alongside pain-score changes, in a study too small to be considered conclusive.
ARA-290 is a synthetic peptide engineered from erythropoietin (EPO), the hormone your kidneys release to stimulate red blood cell production, modified to target inflammation and nerve repair instead.
It works through the innate repair receptor, a separate pathway from the one that makes red blood cells, which is why researchers believe it can deliver EPO’s anti-inflammatory effects without raising blood cell counts.
Your provider reviews your neuropathy history and recent labs to confirm ARA-290 is an appropriate fit before anything is prescribed.
If prescribed, your provider sets your dose and course length, then walks you through subcutaneous injection technique during your kickoff call.
Once administered, ARA-290 binds the innate repair receptor, triggering the same local anti-inflammatory and nerve-protective signaling erythropoietin uses, without affecting red blood cell counts.
Your personal health coach checks in throughout your course to track pain levels and side effects, and your provider adjusts the plan as needed.
No, ARA-290 is not FDA-approved for neuropathy. It remains an investigational peptide, tested in Phase II human trials for sarcoidosis-associated and type 2 diabetes-related small-fiber neuropathy, and your provider can walk you through what that experimental status means for your specific case.
There’s no single standard daily dose, since the human trials used varying concentrations and routes, and the product Dynamis dispenses differs from what any single study tested. Your provider sets your exact dose, injection volume, and course length from your labs and diagnosis, rather than a fixed number that applies to everyone.
ARA-290 is given as a subcutaneous injection, meaning it goes into the fatty tissue just under the skin, typically in the abdomen or the front of the thigh. Your personal health coach walks you through proper technique and site rotation during your kickoff call so you’re comfortable before your first dose.
In the Phase II sarcoidosis trial, ARA-290 patients showed pain-scale improvement within the first week, and the change was statistically significant by week four. That trial used intravenous dosing, though, so your timeline on Dynamis’s subcutaneous protocol may differ, and your provider tracks your response throughout.
No, ARA-290 doesn’t replace standard neuropathy medications like gabapentin or duloxetine; it’s typically considered when those haven’t provided enough relief. Your provider evaluates your current treatment plan and history to decide whether adding it makes sense as part of your broader care.
